Hikma Pharmaceuticals PLC (HKMPY) Stock

About Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC is a global pharmaceutical company that specializes in the development, production, commercialization, and distribution of a wide array of generic, branded, and in-licensed medicines. These pharmaceuticals are provided in various final dosage forms, including solid, semi-solid, liquid, and injectable formats. The company's business activities are organized into three core divisions: Injectables, Generics, and Branded products. The Injectables division primarily supplies generic injectable medications for hospital use. Its Generics segment focuses on offering oral and other non-injectable generic formulations to the retail market. The Branded segment, conversely, delivers branded generic drugs and products licensed from third parties to both retail consumers and hospitals. Hikma's product portfolio addresses numerous therapeutic areas, such as anti-infectives, cardiovascular health, central nervous system conditions, diabetes, oncology, pain management, and respiratory illnesses. The company maintains a substantial international footprint, operating throughout the United Kingdom, the United States, the Middle East, North Africa, Europe, and other global markets. Founded in 1978, Hikma Pharmaceuticals PLC has its headquarters in London, UK.

Hikma Pharmaceuticals PLC is headquartered in GB.

Hikma Pharmaceuticals PLC (HKMPY) stock trades at $42.02 with a market capitalization of $4.40B. The stock is valued at a price-to-earnings (P/E) ratio of 0.19, price-to-book of 1.78, price-to-sales of 1.32. Over the past 52 weeks the stock has ranged between $31.80 and $55.33, and currently trades 24.1% below its 52-week high. It pays a dividend yielding 4.57%.

On profitability, Hikma Pharmaceuticals PLC generates a return on equity (ROE) of 15.83%, above the typical market average, return on capital employed of 13.38%, an operating margin of 16.81%, a net profit margin of 12.00%.

Official website: www.hikma.com